Biggest News Aggregation in the World
📰 Presents News

Page 150 - Presents News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Presents. Real-time updates on events, politics, business and more.

Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of updated findings from the Phase II SUMMIT basket trial of neratinib for HER2 (ERBB2)-mutant, metastatic
United States France General Clairef Friedman Olipriya Das Alanh Auerbach European Commission

Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

TCER IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME In preclinical studies, IMA402 demonstrated enhanced anti-tumor activity
United States France General Twitterand Linkedin Eva Mulder Anja Heuer Carsten Reinhardt

Wugen, Inc.: Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022

-- WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic function -- --
France General Kostenloser Wertpapierhandel Dan Kemp Sergio Rutella Elsie Yau Stern Investor Relations Inc

Bicara Therapeutics Presents New Data from Ongoing Phase 1/1b Trial of Lead First-in-Class Bifunctional Program, BCA101, at the European Society for Medical Oncology (ESMO) Congress 2022

Stage one efficacy threshold achieved in dose expansion in patients with squamous cell carcinoma of the head and neck Webinar to review data to be held Monday, September 12th at 10:30 a.m. ET, featuring
France General Kostenloser Wertpapierhandel Sarah Mccabe Chris Railey Liviu Niculescu Glennj Hanna

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

BioNTech SE: BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO

Follow-up data further demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety and tolerability profile, building on the positive interim data presented at AACR in AprilStrongest
United States Sylke Maas Andreas Mackensen Fosun Pharma Association For Cancer Immunotherapy University Hospital Erlangen

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science